The effect of active acupoints versus inactive acupoints in treating hypertension is not well documented. Metabolic phenotypes, depicted by metabolomics analysis, reflect the influence of external exposures, nutrition, and lifestyle on the integrated system of the human body. Therefore, we utilized high-performance liquid chromatography tandem mass spectrometry to compare the targeted metabolic phenotype changes induced by two different acupoint treatments. The clinical outcomes show that active acupoint treatment significantly lowers 24-hour systolic blood pressure but not diastolic blood pressure, as compared with inactive acupoint treatment. Furthermore, distinctive changes are observed between the metabolomics data of the two groups. Multivariate analysis shows that only in the active acupoint treatment group can the follow-up plasma be clearly separated from the baseline plasma. Moreover, the follow-up plasma of these two groups can be clearly separated, indicating two different post-treatment metabolic phenotypes. Three metabolites, sucrose, cellobiose, and hypoxanthine, are shown to be the most important features of active acupoint treatment. This study demonstrates that metabolomic analysis is a potential tool that can be used to efficiently differentiate the effect of active acupoints from inactive acupoints in treating hypertension. Possible mechanisms are the alternation of hypothalamic microinflammation and the restoration of host-gut microbiota interactions induced by acupuncture.
Background. Coronary heart disease (CHD) is the leading cause of death and disability worldwide. Accumulating evidence reveals that atherosclerosis (AS), characterized by systemic, chronic, and multifocal disease, and is the primary pathological basis of cardiovascular diseases, including CHD. However, the molecular underpinnings of CHD are still far from well understood. Our study attempted to identify aberrant plasma exosome-derived circRNAs and key exosomal circRNA biomarkers for CHD. Methods. The expression profiles of mRNAs, circRNAs, and lncRNAs in the blood exosomes of CHD patients and healthy controls were obtained from the exoRBase database. The corresponding miRNAs of the differentially expressed mRNAs, circRNAs, and lncRNAs were predicted via ENCORI and the miRcode database. LncRNAs/circRNAs and mRNAs with the cotargeted miRNAs were selected to construct an interaction network. Multiple machine learning algorithms have been used to explore potential biomarkers, followed by verification in patients with CHD using real-time quantitative reverse transcription-polymerase chain reaction (RT-qPCR). Results. Based on the cutoff criterion of , we identified 85 differentially expressed circRNAs (4 upregulated and 81 downregulated), 43 differentially expressed lncRNAs (24 upregulated and 19 downregulated), and 312 differentially expressed mRNAs (55 upregulated and 257 downregulated). Functional enrichment analysis revealed that the differentially expressed mRNAs were involved mainly in neutrophil extracellular trap (NET) formation and the nucleotide-binding oligomerization domain- (NOD-) like receptor signaling pathway. Further analysis revealed that the DEGs in the circRNA/lncRNA-miRNA-mRNA interaction network were closely related to lipid and atherosclerotic signaling pathways. Hsa_circ_0001360 and hsa_circ_0000038 were identified as potential biomarkers for CHD based on three machine learning algorithms. The relative expression levels of hsa_circ_0001360 and hsa_circ_0000038 were significantly altered in plasma exosomes from patients with CHD. ROC curve analysis revealed that the areas under the curve (AUCs) were 0.860, 0.870, and 0.940 for hsa_circ_0001360, hsa_circ_0000038, and the two-gene combination, respectively. Conclusion. The circRNA/lncRNA-miRNA-mRNA interaction network might help to elucidate the pathogenesis of CHD. Hsa_circ_0001360 combined with hsa_circ_0000038 might be an important diagnostic biomarker.
Background: Atherosclerosis (AS) is a systemic, chronic and multifocal disease and is the primary pathological basis of cardiovascular diseases, such as coronary heart disease (CHD) and peripheral arterial disease (PAD). Our study attempted to identify aberrant exosome-derived circRNAs in AS and determine their potential clinical value. Methods: The expression of mRNA, circRNA and lncRNA in the blood exosomes of CHD patients and healthy controls was obtained from the exoRBase database. The corresponding miRNAs of mRNA, circRNA and lncRNA were predicted via ENCORI and the miRcode database. The circRNA/lncRNA-miRNA-mRNA interaction network was established based on a competitive endogenous RNA regulatory mechanism. Aberrant circRNAs in the aforementioned network were validated in patients with PAD by real-time quantitative reverse transcription-polymerase chain reaction (RT-qPCR). Results: Based on the cutoff criteria of P<0.05, we identified 85 differentially expressed circRNAs (4 up- and 81 downregulated), 43 differentially expressed lncRNAs (24 up- and 19 downregulated) and 312 differentially expressed genes (55 up- and 257 downregulated). Gene Ontology (GO) analysis revealed that the biological process (BP) terms of the DEGs were significantly enriched in the positive regulation of phosphoprotein phosphatase activity and the positive regulation of protein dephosphorylation. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis demonstrated that DEGs were closely related to the glucagon signaling pathway and estrogen signaling pathway. The relative expression level of hsa_circ_0001360 was significantly downregulated in blood exosomes from patients with PAD, exhibiting an area under the curve of 0.92 (P=0.0283). Conclusion: The circRNA/lncRNA-miRNA-mRNA interaction network might help to elucidate the pathogenesis of AS. Hsa_circ_0001360 was significantly downregulated in blood exosomes in patients with PAD, and this RNA might represent an important diagnostic biomarker of AS.